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Abstract
Classification of primary brain tumors is based mainly on histopathological character‐
istics. Due to the peculiarity of the central nervous system (CNS), the location of the
tumor is also used in the naming of the CNS tumors. These features, histopathology,
and location determine the main prognostic factors in these tumors. Updated molecu‐
lar and genetic findings in the last two decades accumulated vast amount of knowl‐
edge about the biological behavior, response to the treatment, and consequently the
prognosis of CNS tumors. After the clinical use of these data, a recent classification is
proposed  by  the  International  Society  of  Neuropathology  named  as  “integrated
diagnosis.”
This  classification  considers  the  histopathological  classification,  World  Health
Organization  (WHO)  grade  along  with  the  molecular  information.  The  emerging
molecular-genetic data about the CNS tumors will allow the translational researchers
to deliberately understand the oncogenic mechanisms involved in the evolution of these
tumors and judge the optional treatment strategies.
Evaluating the check points of cell cycle and apoptosis provides valuable information
about the tumor biology (tumorigenesis). These mechanisms (pathways) also play an
exclusive role in CNS tumors. Knowledge concerning the gene repressors and gene
activators or some epigenetic changes in proliferative and antiproliferative pathways
that regarded gliomas may yield new individualized treatment options.
In this chapter, we will review the basic and translational research molecular-genetic
data of gliomas with special interest on proliferative and antiproliferative pathways.
Further emerging treatment options and treatment responses in gliomas will be
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critically evaluated with regard to their histopathology, anatomical location, and
molecular-genetic fingerprints.
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1. Introduction
Primary brain tumors are a distinct group of pathologies due to their location, low incidence
compared to other human tumors, histopathologic diversities, and unexpected response to
treatment methods mainly caused by their peculiar genetic and molecular characteristics.
Evaluating new important biomarkers which affect the etiopathogenesis of brain tumors may
also help clinicians in consulting patients about prognosis, potential clinical studies, and
following response to the treatment strategies [1]. Nowadays, the value of early detection of
various types of cancer before metastasis has become a very significant issue. This approach
may increase life expectancy and the quality of life in these patients [2]. It is known that one
of the best management strategies of cancer is to predict its prognosis and response to the
updated therapeutic procedures. In order to achieve this, it is significant to consider the blood,
serum, plasma, or tissue biomarkers. Although the value of liquid biopsy in different human
tumors is established, there is a lack of data regarding primary brain tumors [3]. Confluence
of information suggested that genetic, epigenetic, functional or compositional heterogeneity
of diseased and healthy tissues presented a major challenge to strategies to improve clinical
outcome. [4]. Many molecules found in various fluids, tissues, and cell lines are produced
either by the tumor itself, other tissues, or tumor microenvironment, in response to the
presence of cancer or other associated conditions including inflammation. The scientists study
on cancer search for proper candidate tumor markers and for identifying patients who face
different diagnosis or clinical stages of cancer. This type of biomarkers must have some
characteristics which can be used to estimate tumor volume, determine response to treat‐
ment, and assess disease recurrence through monitoring. Recent advancements have shown
that amplifications/translocations, genetic mutations and changes in microarray-generated
profiles (genetic signatures) are contributory in cancer development, metastasis and develop‐
ment of resistance against different therapeutics. These genetic signatures are referred
according to the type of tumor marker or profile and may be associated with clinical out‐
comes or good prognosis or enhanced quality of life [3,4]. An ideal tumor marker is descri‐
bed as easily measurable, reliable, and cost-effective by use of an assay with high analytical
sensitivity and specificity. Although we have developed a deeper understanding of the
underlying mechanisms, there are only a few markers which have been used in routine
applications and only a limited number of them can be used to identify patients or monitor
progression of cancer types and clinical staging.
Gene overexpression is described as increase in copy number of genes or chromosomes (i.e.,
gene amplification) through increased transcriptional activity. It is known that imbalance
between the gene repressors and gene activators or some epigenetic changes as DNA
methylation or chromosomal translocations can alter transcriptional activity of the gene [3,4].
Neurooncology - Newer Developments146
2. Defined molecular markers which changed our clinical attitude
The use of biomarkers in glioblastoma (GBM) has been evaluated in a recent survey by neuro-
oncologists [5]. Current evidences indicate that MGMT, EGFR, 1p/19q, EGFR, p53, phospha‐
tase and tensin homolog (PTEN) mutation or deletion, EGFRvIII, IDH1/2, PDGFR, and PIK3CA
are the most commonly used markers. But, use of these biomarkers claimed to be prognostic
in GBM cases is still debated. There exist significantly varying clinical representations and
cases of GBM, and the structure of the signaling molecules is highly complex, and therefore,
use of these markers is not very common as of now. In addition, glioblastoma, still a hetero‐
geneous disease, also possesses additional difficulties such as having limited biomarkers to
diagnosis and monitoring and therapeutic options, having poorly understood pathogenesis,
and requiring individualized treatments. On the other hand, the discovery of new biomark‐
ers together with currently used markers can enable us to better stratify patients regarding
treatment paradigms and clinical trials (Figure 1) [6,7].
Figure 1. Some signaling pathways with therapeutic implications in gliomas [7]. Some abbreviations are shown below.
EGF: epidermal growth factor; PIP2, phosphatidylinositol phosphate-2; PIP3, phosphatidylinositol phosphate-2; PKC,
protein kinase C; Grb2, growth factor receptor-bound protein-2; VEGF, vascular endothelial growth factor; S6K, p70 S6
kinase; mTOR, mammalian target of rapamycin; TF, transcription factors; SOS, son of sevenless molecule.
3. Proliferative and antiproliferative pathways and their roles in gliomas
As more and more detailed studies into intracellular signaling cascades and modulators that
regulate these pathways are published, intricacy of the fine-balance between celluar survival
and death is revealed. A revolution in the signaling cascades has provided near complete
resolution of how physiologically important signaling proteins interact with extracellular cues
to trigger proliferation. More detailed understanding of the regulatory and activation
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processes of uncontrolled cellular proliferation is proving to be a key in identification of newer
approaches to improve the efficacy of existing therapeutics. The homeostasis of mitogenic
signaling is tactfully controlled by multiple mechanisms. The past several years have seen a
dramatic leap in our understanding of how Receptor tyrosine kinase (RTK) mediated signaling
is rewired during tumorigenesis to support the transformed phenotype. Activation of RTK
results in receptor dimerization and autophosphorylation. More importantly, docking sites
are created for different adaptor protein complexes such as Grb2/SOS. Mutant Ras is report‐
edly involved in 50% of all human tumors. There are direct pieces of evidence emphasizing
on role of mutant Ras in gliomas. High Ras-GTP levels in advanced astrocytomas have been
reported [8, 9].
Epidermal growth factor receptor (EGFR), coded as a cell-surface-bound receptor, is another
important molecule involved in cell proliferation with potential effects on clinical prognosis
of GBM. It is known that approximately <10% of secondary GBMs and 50% of primary GBMs
have EGFR mutations [10]. The presence of EGFR variant III mutation (EGFRvIII) is known to
upregulate mitogenic signaling pathways. There is a deletion of the regulator N-terminal
domain (฀6–273) of EGFR in this pattern of EGFR. About 10–60% of the patients with GBM
have EGFRvIII which can be detected in the peripheral blood of brain tumors. The detection
of this mutation in brain cancer patients has great importance for anti-EGFRvIII therapies and
patients can be monitored to track their response to these therapies [11,12]. Better and deeper
knowledge of mechanistic insights that cause EGFR heterogeneity in GBM will prove to be
helpful in identification of drugs with maximum efficacy. EGFRvIII mutation to identify
patients for treatments such as erlotinib therapy for non-small cell lung cancer or RNA-directed
treatments and vaccine therapies [13]. As of now, we still have a limited knowledge about
downstream signaling pathways for EGFR and whether EGFR mutations affect these down‐
stream signaling pathways, such as AKT, MAPK, and STAT3. On the other hand, it has been
suggested that the clinical utility of this biomarker and its use for targeted treatment are
complicated [1].
Platelet-derived growth factor receptor (PDGFR), a cell-surface tyrosine kinase, plays role in
GBM proliferation and stem cell renewal. There are multiple isoforms of PDGFR, mutated in
up to 30% of GBMs. One of them, the most significant one regarding GBM, is PDGFRA. The
other isoform is also PDGFRAD (with a deletion of exons 8 and 9), seen in 40% of GBMs, and
leads to constitutive activation [14,15]. According to the Cancer Genome Atlas, PDGFRA has
a crucial role in the proneural subtype of GBM; however, no changes were observed in
prognosis of the evaluated patients [16].
The phosphatidylinositol 3-kinase (PI3K)/AKT (PI3K/AKT) pathway is known as a crucial
intracellular signaling pathway, taking role in regulating cell proliferation, migration,
quiescence, proliferation, cancer, and longevity [17]. PI3K is an enzyme which phosphory‐
lates phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphos‐
phate (PIP3) at the cell inner membrane. This activation process leads to recruit and upregulate
various downstream pathways including AKT, a molecule localized in the plasma mem‐
brane [18].
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Phosphatase and tensin homolog (PTEN) is known as a natural inhibitor of PI3K/AKT
pathway. It has been shown to inhibit transduction of signals to downstream effectors via
dephosphorylation of PIP3 to PIP2 [19]. It has been reported that an increased PI3K/Akt/mTOR
signaling is seen in ~88% of all glioblastomas [20,21]. All of these biological pathways has been
related to genetic alterations of key regulatory molecules involved in mitogenic signaling in
RTKs and also in the PI3K-PTEN-Akt signaling axis.
Some regulatory and effector molecules play important role in classical cell death networks of
both extrinsic (death receptor-mediated) and intrinsic (mitochondria-dependent) apoptosis
signaling pathways [22]. Since the discovery of TNF (Tumor Necrosis Factor) family mem‐
bers, a new milestone in apoptosis-inducing cancer therapies has emerged. TRAIL (tumor
necrosis factor-related apoptosis-inducing ligand) is a protein reportedly involved in selec‐
tive killing of cancer cells while leaving normal cells intact. The major biological role of this
281-amino acid-type II transmembrane protein is apoptosis induction after interacting with its
receptors to trigger extrinsically and intrinsically controlled pathways. Four different
homologous human TRAIL receptors have been categorized into TRAIL-R1/DR4, TRAIL-R2/
DR5 also known as Killer, TRAIL-R3 or DcR1, and TRAIL-R4 or DcR2. Substantial fraction of
information has been added into the existing pool of knowledge related to TRAIL biology and
known that different cancers are resistant to TRAIL-based therapeutics. Mechanistically it has
been shown that downregulation of death receptors considerably impaired TRAIL-induced
apoptosis in cancer cells. In the upcoming section, we briefly summarize advancements in our
understanding related to the underlying mechanisms of resistance against TRAIL-induced
apoptosis. We also discuss how TRAIL has shown as a potent anticancer agent in xenograft‐
ed mice. Natural products have also added more options in the armory against brain tumor.
Detailed mechanistic insights have provided a near complete resolution of protein network
TRAIL-resistant glioblastoma and increasingly it is being realized that imbalance of stoichio‐
metric ratios of proapoptotic and antiapoptotic proteins modulates response of cancer cells to
TRAIL. Previously, it has been convincingly revealed that Znf domain of A20 E3 ligase
ubiquitinated RIP1 through a K63-linked polyUB chain that structurally interacted with p18
domain of caspase-8 and blocked its dimerization and cleavage. Functionally inactive
caspase-8 was unable to proteolytically process downstream effectors that resulted in
impairment of TRAIL-induced apoptosis in glioblastoma [23]. Adeno-associated virus (AAV)
vectors are being used to efficiently deliver secreted, soluble TRAIL in different preclinical
studies. Additionally, these are also used in combination with TRAIL-sensitizing cardiac
glycoside, lanatoside C (lan C). Tumor growth was considerably reduced in intracranial U87
tumor-bearing mice treated with AAV-sTRAIL and lanatoside C [24]. Mesenchymal stem
cells (MSCs) have the ability to migrate toward intracranial glioma xenografts. Experimental‐
ly verified data indicated that MSCs expressing firefly luciferase (fluc) injected into the left
hemisphere migrated rapidly toward right, tumor-bearing region of the brain. Results revealed
that 11% of implanted MSCs were noted to be localized in right hemisphere within 2 hours
after MSC inoculation. Coculture of GBM43 and U87 glioma cells with MSCs-TRAIL dis‐
played notable rise in caspase-3 activity. Survival rate of tumor-bearing mice was enhanced
intranasally delivered with MSCs-TRAIL [25]. Carbenoxolone (CBX), a derivative of 18-
glycyrrhetinic acid, has been shown to effectively enhance killing activity of TRAIL-express‐
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ing MSCs. CBX considerably upregulated cell-surface expression of DR5 in CBX-treated
ΔGli36 and U87MG cells. CBX also inhibited gap junction (GJ) communication via modula‐
tion of connexin (Cx43). CBX remarkably reduced expression levels of Cx43 in U87MG and
ΔGli36 cells after 72 hours. Results revealed that TRAIL-induced apoptosis was markedly
higher in cells transfected with Cx43-siRNA [26] .
Antibody-based anticancer therapies have attracted considerable attention and different
structural variations are being tested for efficacies which involve smaller antibody frag‐
ments such as ScFvs, Fabs, and nanobodies. Single-chain Fv fragment (scFv) consists of a
variable light-chain (VL) and variable heavy-chain (VH) domains, which contains whole
antigen-binding site.
Multidrug resistance protein 3 (MRP3) is frequently overexpressed in glioblastoma multi‐
forme cells. scFvM58-sTRAIL is an engineered protein formed by fusion of MRP3-specific scFv
antibody M58 with N-terminus of soluble TRAIL. scFvM58-sTRAIL was effective against
MRP3-positive GBM cells. Expectedly, scFvM58-sTRAIL did not show significant activity
against MRP3-negative Jurkat cells. These results indicated that scFvM58-sTRAIL was
effective against MRP3-positive cancer cells [27].
Various bivalent EGFR-targeting nanobodies (ENbs) have been designed and noted to be
effective. Neural stem cells (NSC) are potent agents to deliver ENbs. Preclinical study revealed
that tumor regression was significantly higher in xenografted mice treated with NSC-ENb2-
TRAIL. Xenografted mice survived for 51 days upon treatment with control NSC-ENb2 and
80% of mice survived for 80 days after treatment with NSC-ENb2-TRAIL. These findings
indicated that tumoritropic NSC-releasing ENb2 inhibited growth of glioblastoma and
effectiveness of ENb2-based therapy was markedly improved by NSC-releasing ENb2-
TRAIL [28].
Diethylamino-curcumin mimics with substituted triazolyl groups have previously been
synthesized and reported to effectively sensitize resistant CRT-MG astroglioma cells to
TRAIL [29].
Gingerol, a major bioactive component of ginger, has been shown to trigger expression of DR5
in a p53-dependent manner in U87 glioblastoma cells. Digitoxin (DT), a clinically approved
cardiac glycoside, has been observed to overcome resistance against TRAIL in resistant U87MG
glioblastoma cells. Digitoxin effectively enhanced DR5 expression on cell surface of resistant
cancer cells [30].
4. Natural products mediated targeting of proliferative protein network
in glioblastoma
Crude hydromethanolic extracts produced by maceration of Spartium junceum flowers and
Onopordum acanthium leaves were tested for anticancer activity against glioblastoma U-373
cancer cells. O. acanthium was effective against glioblastoma cells and induced apoptosis [31] .
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Aqueous extract of Ruta graveolens L. notably enhanced phosphorylated ERK1/2 and Akt levels
in glioma cells. The results indicated that Ruta graveolens exerted inhibitory effects via
activation of ERK1/2 and Akt-induced signaling pathways [32].
Triterpenoid saponins from Albizia lebbeck (L.) showed activity against TG1 and U-87 MG
cancer cells with IC50 values of 2.10 and 2.24 μM for compound 2 and 3.46 and 1.36 μM for
compound 1 [33].
Isocitrate Dehydrogenase 1 and 2 (IDH1/2) are two important enzymes involved in the Krebs
cycle and oxidatively decarboxylate isocitrate to produce a-ketoglutarate and CO2. IDH1 is a
cytosolically located protein. IDH2 encodes a mitochondrial protein. Parsons et al. reported
that IDH1/2 was mutated in approximately 60–80% of secondary gliomas and 5% of primary
gliomas [34]. There are two common IDH mutation (IDH1R132H and IDH2172 mutations)
types. It has been reported that these mutations are seen in GBM (>90% samples with IDH1/2
mutation). These mutations lead to increased production of the oncometabolite D-2-hydrox‐
yglutarate. This metabolite has previously been noted to modify DNA methylation patterns
in GBM and transcriptional activity of different target genes [35]. IDH1 mutation may be
correlated with several clinical factors such as younger patient age and frontal location. It has
also been reported that additional survival benefit (median survival 9.75 years) was ach‐
ieved from greater tumor resection (<5 cm3 residual) in IDH1 mutants, except for wild-type
IDH1. It has also been suggested that the presence of IDH1/2 mutation supports increased
therapeutic efficacy with chemoradiotherapy and greater resection [1]. When IDH mutations
occur, enzymatic activities of some important molecules can be altered. While alpha-ketoglu‐
tarate (α-KG) is decreased, produced 2-hydroxyglutarate (2-HG) can inhibit the activity of
some enzymes. These enzymes play a significant role in regulating DNA and histone meth‐
ylation (α-KG-dependent dioxygenase), including histone demethylases and the TET family
of 5mC hydroxylases [36–38].
TET proteins are described as a new class of enzymes which can alter the methylation status
of the DNA by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC). The
biological function of 5hmC is not clear. It has been suggested that it is an intermediate in DNA
demethylation process. 5hmC offers remarkable reduction in human gliomas as compared to
normal brain. An inverse relationship has been reported between 5hmC levels and cell
proliferation [39,40].
p53 is a very important protein involved in many physiological and pathological process in
the regulation of cell viability in terms of cell cycle, apoptosis, cell differentiation, and other
mechanisms of cell regulation during exposure to DNA-damaging agents (e.g., ultraviolet
radiation, toxins, chemotherapeutic agents) [1]. It has been reported that P53 gene is mutat‐
ed in 28% of primary GBMs [41]. There are three patterns regarding p53 dysfunction. One is
called loss of function. This pattern may describe a lot of endogenous growth inhibitor effects
of wild-type p53. The other is gain of function. This means that mutant p53 upregulates a
distinct subset of genes from wild-type p53. The last one is dominant-negative effects of p53.
It is associated with a tetramer pattern of mutant p53/wild-type p53 and leads to downregu‐
late activity [42]. It is known that some other mechanisms of p53 inactivation include muta‐
tions of its modulators including MDM2 inhibitor or deletion of p14ARF [43,44]. Whether there
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is a correlation between p53 and GBM prognosis is still unclear due to the complexity of the
p53 signaling pathway. P53 pathway includes many important regulators and the heteroge‐
neity of p53 mutation types can also affect the p53 molecule. Because of those mentioned,
therapies targeting P53 have been limited in this field [42].
The deletion of 1p and 19q, occurring early in tumorigenesis, is known as an important genetic
signature. The deletion is seen in 50–70% of patients with low-grade oligodendrogliomas. This
can be predictive for the tumor’s chemosensitivity to some agents [46,47]. It has been report‐
ed that P190RhoGAP, localized on 19q13.3, can be one of the candidate genes as a tumor
suppressor [48]. A large-scale genomic analysis by array CGH has reported two different
patterns about 1p deletion for prognostic factors. One of them is the whole 1p (associated with
the deletion of the whole 19q). This may be associated with a good prognosis for oligoden‐
drogliomas. Another is 1p deletion (not associated with 19q loss). This deletion has a nega‐
tive prognostic value and improves progression-free survival (PFS) and overall survival (OS).
It is mostly associated with astrocytomas [49]. It is also related to the response to chemother‐
apy and radiation in oligodendroglioma. Data obtained from EORTC 26951 and RTOG 9402
trials showed an improvement in OS with the addition of radiation to procarbazine/lomus‐
tine/vincristine chemotherapy in anaplastic oligodendroglioma with 1p/19q mutation [50].
There are some studies correlated with these similar findings, In GBM, similar findings have
been demonstrated in some studies [51,52], but not in others [53,54]. It has also been report‐
ed that codeletion of 1p and 19q is related with IDH1 mutation and MGMT hypermethyla‐
tion [47,55].
O-6-Methylguanine-DNA-methyltransferase (MGMT) is involved in removal of alkylation at
the O6 position of guanine. Hypermethylation of MGMT transcriptionally down-regulated its
expression. This situation results in impaired repair capability response to chemotherapeutic
agents and radiation. Some clinical trials have confirmed the prognostic and predictive roles
of MGMTm [56]. It has been suggested that patients with MGMTm are responsive to chemo‐
therapy. However, MGMT status was not distinguished between patients with glioblastoma
(GBM) and those with anaplastic astrocytoma (AA) and this restricts interpretation of the
study. The European Organisation for Research and Treatment of Cancer (EORTC)
26981/22981 and National Cancer Institute of Canada (NCIC) trials also indicates increased
responsiveness to temozolomide for patients with MGMTm [57]. It has been suggested that a
standard marker both following prognosis and identifying patients for clinical trials, in which
alkylation therapies and/or radiation therapy are applied, may be used for MGMTm [1].
5. Epigenetics in human gliomas with some details
Acetylation of lysine residues is a post-tranlational modification controlled by the opposing
action of histone deacetylases (HDACs) and histone acetyl transferases (HATs) [58–60].
Histone methylation may generally occur on the side chains of lysines and arginines, which
can alter the activity of effector proteins of the transcriptional machinery [58–60]. It has been
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reported that some mutations in some regulatory genes such as HDACs (HDAC2 and
HDAC9), histone demethylases (JMJD1A and JMJD1B), and histone methyltransferases (SET7,
SETD7, MLL, MLL3, and MLL4) have been detected to a large extent in genomic analysis of
GBM samples [34]. However, it is still unclear whether histone modifications play signifi‐
cant roles in gliomas and their potential can serve as biomarkers and/or therapeutic targets.
Noncoding RNAs are known to play an important role in the epigenetic regulation of gene
expression [61,62].
One group of RNAs are described as microRNAs (miRNAs). miRNAs are important regulators
for gene expression. miRNAs post-transcriptionally regulate expression of target genes.
miRNAs are double-stranded RNA molecules of approximately 22 nucleotides (nt) in length.
miRNA binds to specific recognition sequences within the 3’-untranslated region (3’-UTR) of
target mRNAs [61–63]. miRNAs are characterized functionally into tumor suppressors and
oncogenic miRNAs. Tumor suppressor miRNAs are frequently down-regulated in gliomas as
compared to normal brain [64–67]. In contrast, some miRNAs are defined as oncogenes with
enhanced expression in glioma such as miR-21, targeting regulators, miR-10b and miR-221,
targeting cell cycle inhibitors, miR-30e, and targeting IjBa [68–71]. It has been suggested that
there is a link between miRNAs and well-known stem cell-regulating proteins [72]. It has also
been reported that miR-17-92 plays a critical role in regulation of glioma stem cell (GSC)
differentiation, apoptosis, and proliferation [73]. miR-451 expression reduced notably in cancer
cells kept in low glucose conditions. Results revealed that cancer cells kept in low glucose
conditions had reduced cell proliferation but an enhanced rate of cell migration and survival
in glioblastomas. Glucose sufficiency induced upregulation of miR-451 notably inhibited
LKB1/AMPK pathway activation [74]. miR-128, downregulated in glioblastoma tissue, has a
tumor-suppressive function. Both in vitro and in vivo, miR-128 expression significantly
reduces glioma cell proliferation via downregulation of Bmi-1 oncogene, a component of the
polycomb repressor complex (PRC). In addition, miR-128 inhibits GSC self-renewal [75]. The
PRC has been shown to induce normal and cancer stem cell self-renewal and plays role in GSC
regulation [76]. When miR-124 has overexpression, it can inhibit the CD133+ cell
subpopulation of the neurosphere and downregulate stem cell markers, such as BMI1, Nanog,
and Nestin [77]. Both miR-124 and miR-137 are up-regulated during adult neural stem cell
differentiation and down-regulated in high-grade gliomas [78]. Although there are
comprehensive studies about miRNa in gliomas, it should not be forgotten that one miRNA
can affect the expression of various target genes. It must be reconsidered in terms of several
important aspects before miRNAs may be used therapeutically [79].
LncRNAs which have more than 200 nucleotides and are up to 100 kb in length are described
as an important RNA molecule that plays role in some biological cellular actions such as
stemness, development, and cell survival [80–82]. Maternally expressed gene 3 (MEG3) is a
maternally expressed imprinted gene that can also act as an lncRNA. Its expression in glioma
tissues is lower than that in normal adjacent tissues [83]. The tumor-suppressive role of MEG3
is confirmed by the fact that it can associate with p53. It is known that this association is needed
for p53 activation [84].
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6. Possible relationships between location and genetic signature in primary
brain tumors
A unique finding is that the location of certain primary brain tumors determines their genetic
characteristics. Cranial base meningiomas are less malignant compared to the non-cranial base
meningiomas [85]. The frequencies of grade II and III cranial base and non-cranial base
meningiomas are 3.5 and 12.1%, respectively. These findings origin from a clinical-patholog‐
ical observation. The biological, molecular, and genetic basis of this fact requires further
explanation. A simple answer would be the diverse embryological origins of the dura mater
in various locations of human skull [86]. A recently published paper showed (utmost)
intriguing data about meningioma biology, which is going to help our understanding of this
tumor, of which 85–90% is classified as benign (grade I), but has in certain locations an
aggressive course. Meningiomas regarding their genetic origin are divided as NF2 and non-
NF2 meningiomas. The non-NF2 meningiomas behave clinically different and are generally
always benign, with chromosomal stability, and originate from the medial skull base. In
contrast to these findings, meningiomas with mutant NF2 and/or chromosome 22 loss are more
likely to be atypical and demonstrate genomic instability and are localized to the cerebral and
cerebellar hemispheres. This group concludes their study: “Collectively, these findings
identify distinct meningioma subtypes, suggesting avenues for targeted therapeutics” [87].
There is a mutational profile of a meningioma, which can be predicted based on its anatomi‐
cal location in human calvarium. This finding may provide a unique treatment strategy for
midline tumors, which may have a response to medical treatment like hedgehog inhibitors.
There are treatment-resistant meningiomas, which are surgically unresectable, recurrent, or
invasive. In these patients one can reserve surgery or irradiation, bearing in mind that there is
an independent risk factor for progression of these generally benign considered primary brain
tumors. This location-based molecular and genetic data provides an updated information
about prognosis and treatment response of meningiomas. This update research, which is
collected over 300 meningiomas, is a valuable finding, regarding designing personalized
management strategies for meningiomas.
Another fact about meningioma is that there is a subgroup of meningiomas, which are
histopathologically classified as grade I meningioma, but recurs during follow-up in a short
distance unexpectedly as grade II and later as grade III meningiomas. Although the malig‐
nant progression of gliomas is considerably well defined and researched entity, there is lack
of scientific data about meningiomas, regarding which one is going to transform malignant‐
ly. Al-Mefty et al. explained this clinical observation with their FISH analysis of primary and
recurring meningiomas with malignant progression in their series. They studied 175 recur‐
rent meningiomas and found that 11 tumors showed histopathologically verified progres‐
sion to a higher grade. In this study, the cytogenetic analysis with FISH showed deletions of
22, 1p, and 14q. The interesting finding was that in all but one case, these aberrations have
been shown to be also present in the previous specimen despite their lower histopathologi‐
cal grades [88].
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The conclusion of this translational paper from 2004 was defined: “Tumors that present with
complex genetic alterations, even those with a benign histopathological grade are potential‐
ly aggressive and require closer follow-up.” After 12 years this sentence is still valid for
meningiomas and other primary brain tumors, which are genetically prone to upgrade. The
designated malignant progression of primary brain tumors is an important issue for design‐
ing molecular-genetic-based therapeutic approaches in the near future. The finding that
oligodendrogliomas show allelic deletions on 19q and 1p has been defined in 1994 by
Reifenberger et al. [89]. Clinical relevance and its implication in changing management
strategies followed this genetic finding. The chemotherapeutic response and survival in
patients with anaplastic oligodendrogliomas were explained with the over-mentioned genetic
background [90]. Its relationship with better prognosis and response to chemotherapy is today
an established fact and will be considered in the update “integrated-layered” classification of
central nervous system tumors after Haarlem consensus [91]. The location of oligodendro‐
gliomas and its relationship with 1p19q deletion further changed our direction in a phyloge‐
netic explanation of primary brain tumor development and coexisting molecular-genetic
mechanisms. Frontal location of oligodendroglioma was suggested to be a favorable prognos‐
tic factor. The accumulated data clearly demonstrated that frontal location was strongly
correlated with 1p19q deletion [92]. Prognostic variables in oligodendroglial tumors: a single-
institution study of 95 cases. This translational information eased (helped) to predict the
prognosis of these peculiar tumors. The embryological developmental basis of oligodendro‐
glioma and its molecular-genetic relationship are other issues, which require further investi‐
gation.
Lucius Annaeus Seneca, known as Seneca the Younger (c. 4 BC–AD 65), stated: “No one can
wear a mask for very long.” We can further apply this wise quote to our update neuro-
oncological approach, which requires redefinition in the coming decades: “No tumor can wear
a mask for very long.” The molecular-genetic data and determining its relationship with
primary brain tumors will further relieve “the mask” of the primary brain tumors. The
upcoming new WHO classification of central nervous system tumors will consider this issue.
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